• 1
    Goldring SR, Gravallese EM. Mechanisms of bone loss in inflammatory arthritis: diagnosis and therapeutic implications. Arthritis Res 2000; 2: 337.
  • 2
    Peel NF, Spittlehouse AJ, Bax DE, Eastell R. Bone mineral density of the hand in rheumatoid arthritis. Arthritis Rheum 1994; 37: 98391.
  • 3
    Westhovens R, Dequeker J. Rheumatoid arthritis and osteoporosis. Z Rheumatol 2000; 59 Suppl 1: 338.
  • 4
    Goldring SR. Periarticular bone changes in rheumatoid arthritis: pathophysiological implications and clinical utility. Ann Rheum Dis 2009; 68: 2979.
  • 5
    Guler-Yuksel M, Bijsterbosch J, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Hulsmans HM, de Beus WM, et al. Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis. Ann Rheum Dis 2008; 67: 8238.
  • 6
    Hoff M, Haugeberg G, Kvien TK. Hand bone loss as an outcome measure in established rheumatoid arthritis: 2-year observational study comparing cortical and total bone loss. Arthritis Res Ther 2007; 9: R81.
  • 7
    Deodhar AA, Brabyn J, Jones PW, Davis MJ, Woolf AD. Longitudinal study of hand bone densitometry in rheumatoid arthritis. Arthritis Rheum 1995; 38: 120410.
  • 8
    McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006; 354: 82131.
  • 9
    Hoff M, Haugeberg G, Odegard S, Syversen SW, Landewe R, van der Heijde D, et al. Cortical hand bone loss after one year in early rheumatoid arthritis predicts radiographic hand joint damage at 5 and 10 year follow-up. Ann Rheum Dis 2009; 68: 3249.
  • 10
    Deodhar AA, Woolf AD. Bone mass measurement and bone metabolism in rheumatoid arthritis: a review. Br J Rheumatol 1996; 35: 30922.
  • 11
    Forslind K, Keller C, Svensson B, Hafstrom I. Reduced bone mineral density in early rheumatoid arthritis is associated with radiological joint damage at baseline and after 2 years in women. J Rheumatol 2003; 30: 25906.
  • 12
    Haugeberg G, Green MJ, Quinn MA, Marzo-Ortega H, Proudman S, Karim Z, et al. Hand bone loss in early undifferentiated arthritis: evaluating bone mineral density loss before the development of rheumatoid arthritis. Ann Rheum Dis 2006; 65: 73640.
  • 13
    Ardicoglu O, Ozgocmen S, Kamanli A, Pekkutucu I. Relationship between bone mineral density and radiologic scores of hands in rheumatoid arthritis. J Clin Densitom 2001; 4: 2639.
  • 14
    Kalla AA, Meyers OL, Chalton D, Heath S, Brown GM, Smith PR, et al. Increased metacarpal bone mass following 18 months of slow-acting antirheumatic drugs for rheumatoid arthritis. Br J Rheumatol 1991; 30: 91100.
  • 15
    Jensen T, Klarlund M, Hansen M, Jensen KE, Podenphant J, Hansen TM, et al. Bone loss in unclassified polyarthritis and early rheumatoid arthritis is better detected by digital x ray radiogrammetry than dual x ray absorptiometry: relationship with disease activity and radiographic outcome. Ann Rheum Dis 2004; 63: 1522.
  • 16
    Bottcher J, Pfeil A, Heinrich B, Lehmann G, Petrovitch A, Hansch A, et al. Digital radiogrammetry as a new diagnostic tool for estimation of disease-related osteoporosis in rheumatoid arthritis compared with pQCT. Rheumatol Int 2005; 25: 45764.
  • 17
    Campagnuolo G, Bolon B, Feige U. Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis. Arthritis Rheum 2002; 46: 192636.
  • 18
    Ominsky MS, Kostenuik PJ, Cranmer P, Smith SY, Atkinson JE. The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys. Osteoporos Int 2007; 18: 107382.
  • 19
    Ross AB, Bateman TA, Kostenuik PJ, Ferguson VL, Lacey DL, Dunstan CR, et al. The effects of osteoprotegerin on the mechanical properties of rat bone. J Mater Sci Mater Med 2001; 12: 5838.
  • 20
    Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 30919.
  • 21
    Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, et al, for the Denosumab Rheumatoid Arthritis Study Group. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008; 58: 1299309.
  • 22
    Dore RK, Cohen SB, Lane NE, Palmer WR, Shergy W, Zhou L, et al. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis 2009. E-pub ahead of print.
  • 23
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 24
    Peterfy C, Wu C, Jiang Y, Tuttle D, Kothari M, Sieffert M, et al. Inter-reader reproducibility of MRI scoring of erosion progression in rheumatoid arthritis using an expanded scale [abstract]. Ann Rheum Dis 2006; 65 Suppl II: 591.
  • 25
    Lassere M, McQueen F, Ostergaard M, Conaghan P, Shnier R, Peterfy C, et al. OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging studies. Exercise 3: an international multicenter reliability study using the RA-MRI score. J Rheumatol 2003; 30: 136675.
  • 26
    Sharp JT, Young DY, Bluhm GB, Brook A, Brower AC, Corbett M, et al. How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum 1985; 28: 132635.
  • 27
    Van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000; 27: 2613.
  • 28
    Bruynesteyn K, Boers M, Kostense P, van der Linden S, van der Heijde D. Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change. Ann Rheum Dis 2005; 64: 17982.
  • 29
    Green MJ, Deodhar AA. Bone changes in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2001; 15: 10523.
  • 30
    Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 16576.
  • 31
    Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004; 19: 105966.
  • 32
    Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008; 93: 214957.
  • 33
    Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 2007; 22: 183241.
  • 34
    Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008; 43: 2229.
  • 35
    Body JJ, Facon T, Coleman RE, Lipton A, Geurs F, Fan M, et al. A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006; 12: 12218.
  • 36
    Fizazi K, Lipton A, Mariette X, Body JJ, Suarez T, Rahim Y, et al. A randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasm after intravenous bisphosphonates. J Clin Oncol 2008; 27: 156471.
  • 37
    Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007; 25: 44317.
  • 38
    Jorgensen JT, Andersen PB, Rosholm A, Bjarnason NH. Digital x-ray radiogrammetry: a new appendicular bone densitometric method with high precision. Clin Physiol 2000; 20: 3305.
  • 39
    Brower AC. Use of the radiograph to measure the course of rheumatoid arthritis: the gold standard versus fool's gold. Arthritis Rheum 1990; 33: 31624.
  • 40
    Bottcher J, Pfeil A, Rosholm A, Schafer ML, Malich A, Petrovitch A, et al. Computerized digital imaging techniques provided by digital x-ray radiogrammetry as new diagnostic tool in rheumatoid arthritis. J Digit Imaging 2006; 19: 27988.
  • 41
    Bottcher J, Pfeil A, Rosholm A, Soros P, Petrovitch A, Schaefer ML, et al. Computerized quantification of joint space narrowing and periarticular demineralization in patients with rheumatoid arthritis based on digital x-ray radiogrammetry. Invest Radiol 2006; 41: 3644.
  • 42
    Barnett E, Nordin BE. The radiological diagnosis of osteoporosis: a new approach. Clin Radiol 1960; 11: 16674.
  • 43
    Bottcher J, Malich A, Pfeil A, Petrovitch A, Lehmann G, Heyne JP, et al. Potential clinical relevance of digital radiogrammetry for quantification of periarticular bone demineralization in patients suffering from rheumatoid arthritis depending on severity and compared with DXA. Eur Radiol 2004; 14: 6317.
  • 44
    Hoff M, Kvien TK, Kalvesten J, Elden A, Haugeberg G. Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study. Ann Rheum Dis 2009; 68: 11716.